

1 **Title**

2 High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.

3

4 **Authors**

5 Simon P Keam^{1,2,4*}, Heloise Halse^{2*}, Thu Nguyen², Minyu Wang², Nicolas Van Kooten Losio², Catherine
6 Mitchell³, Franco Caramia¹, David J Byrne³, Sue Haupt^{1,4}, Georgina Ryland³, Phillip K Darcy^{2,4}, Shahneen
7 Sandhu⁵, Piers Blombery^{3,4}, Ygal Haupt^{1,4,6}, Scott G Williams^{7#}, Paul J Neeson^{2,4#}.

8 **Affiliations**

9 1. Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.

10 2. Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia.

11 3. Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia.

12 4. Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.

13 5. Genitourinary Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

14 6. Department of Biochemistry and Molecular Biology, Monash University, Australia.

15 7. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Aus-
16 tralia.

17

18 * Denotes shared first author

19 # Denotes shared senior author

20 **Running title:**

21 Prostate cancer brachytherapy induces a tissue inflammation response

22 **Keywords:**

23 Prostate, cancer, radiotherapy, T cells, immune checkpoint

24 **Corresponding author:**

25 Paul J Neeson, Cancer Immunology Research, Peter MacCallum Cancer Center, 305 Grattan St, Parkville,
26 Melbourne, 3000, Australia. Phone: +61 03 85597101, FAX: +61 03 85595459.

27 E-mail: paul.neeson@petermac.org

28 **Conflict of Interest Statement:**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 The authors have no conflicts of interest to declare.

1 **Author contributions**

2 S.P.K., H.H., S.G.W. and P.J.N conceived and designed the study. S.P.K., H.H., T.N., N.V.K.L., D.J.B. and
3 G.R. performed experiments. S.P.K., M.W. and F.C. performed bioinformatic and statistical analyses. C.M.
4 performed uropathological inspection. S.P.K. and P.J.N. drafted the manuscript. S.P.K., H.H., P.J.N., SH.,
5 Y.H., C.M., D.B., G.R., P.K.D., S.S. and P.B. critically revised the manuscript.

6
7 **Acknowledgements**

8 The authors would like to thank the Molecular Genomics Facility and the Centre for Advanced Histology and
9 Microscopy at the Peter MacCallum Cancer Centre for their assistance with performing experiments.

10
11 **Funding**

12 This study was funded by the PeterMac Foundation, the Victorian Cancer Agency, a Prostate Cancer Founda-
13 tion USA (Creativity award), Cancer Council Victoria (Grant-In-Aid) and an NHMRC Program Grant.

14
15 **Availability of data and materials**

16 The datasets used and/or analysed during the current study are available from the corresponding author on
17 reasonable request

1 **Abstract**

2 Prostate cancer (PCa) has a profoundly immunosuppressive microenvironment, we hypothesized that radiation
3 therapy would break this immune suppression. To investigate this, we performed high-throughput immune cell
4 subset analysis, and gene expression profiling of pre- versus post-radiation tissue in a cohort of patients with
5 localized disease that received high dose-rate brachytherapy (HDRBT). We resolved tumor and non-tumor
6 zones in our spatial analysis to explore what drives the immunological response. Nanostring immune profiling
7 revealed numerous immune checkpoint molecules were stimulated in response to HDRBT (e.g. B7-H3,
8 CTLA4, PDL1 and PDL2). A published 16-gene tumor inflammation signature (TIS) gene profiling of immune
9 activation states (high:*hot*, intermediate and low:*cold*) showed that most tissues possessed a low TIS pre-
10 HDRBT. Crucially, HDRBT converted 80% of these ‘cold’-phenotype tumors into an ‘intermediate’ or ‘hot’
11 class. We used digital spatial profiling to show these HDRBT-induced changes in prostate TIS scores were
12 derived from the non-tumor regions. Furthermore, these changes in TIS were also associated with pervasive
13 changes in immune cell density and spatial relationships – in particularly between T cell subsets and antigen
14 presenting cells. We identified increased density of CD4⁺ FOXP3⁺ T cells, CD68⁺ macrophages and CD68⁺
15 CD11c⁺ dendritic cells in response to HDRBT. The only subset change in tumor zones was PDL1⁺
16 macrophages. While these immune responses were heterogeneous, HDRBT induced significant changes in
17 immune cell associations, including a gained T cell and HMWCK⁺ PDL1⁺ interaction in tumor zones. In
18 conclusion, we showed HDRBT has a clear impact in converting “cold” prostate tumors into more
19 immunologically activated “hot” tissues, with accompanying spatially-organized immune infiltrates and
20 signaling changes. Understanding and potentially harnessing these changes will have widespread implications
21 for the future treatment of localized PCa and the possible use of combination immunotherapies.

22

23

1 **Introduction**

2 Standard curative-intent treatment options for localized prostate cancer include radical prostatectomy or
3 radiotherapy [1]. Radiation therapy is delivered using external beam radiotherapy (EBRT) or via radioactive
4 sources implanted within the prostate (brachytherapy). High-dose-rate brachytherapy (HDRBT) uses a
5 temporary prostate implant to deliver high doses of radiation over a short time, achieving a high tumor dose
6 while minimizing radiation exposure to nearby normal tissue, while often employing an additional short course
7 of EBRT to treat surrounding tissues.

8 HDRBT enables substantially higher doses (upwards of 10Gy per fraction usually) to be delivered to the
9 prostate than those typically used with EBRT (1.8-2.0Gy per fraction) and exploits the known sensitivity of
10 PCa to such large fractional doses [2]. This relative resistance to conventional low doses of EBRT has historically
11 been attributed to an enhanced ability of PCa to repair sublethal DNA damage [3]. This results in excellent
12 responses for the majority of patients, however at least a third of men will ultimately relapse [4] and progress to
13 advanced and incurable disease.

14 Normal prostate has an immune infiltrate characterized by intra-epithelial lymphocytes in the prostate glands,
15 and low numbers of lymphocytes and macrophages distributed throughout the interstitial tissue [5]. Localized
16 PCa has an immunosuppressed phenotype, where tumor-associated lymphocytes are present at the tumor
17 margin, with only sparse numbers within the tumor [6]. This suggests that an anti-tumor immune response
18 exists in these patients, but is held in check by the immunosuppressed prostate tumor.

19 In addition to direct effects on tumor cells and supporting stromal cells, radiotherapy can provoke
20 immunological effects [7]. Clinical evidence of this can be found in case studies where distant untreated
21 metastases undergo apparent spontaneous regression post-radiotherapy of an index lesion; an abscopal effect
22 [8]. This is thought to be mediated via a systemic immune response triggered by the initial RT. The
23 mechanisms implicated include immunogenic tumor cell death, antigen cross presentation and T cell priming
24 to tumor-derived antigens [9]. However, there is pre-clinical evidence that hypo- and hyper-fractionated RT
25 have different immunological effects on tumor tissue. Specifically, that high dose-rate hypo-fractionated
26 radiation, which includes HDRBT, can break immunosuppressive tumor microenvironments, promote immune
27 cell infiltration, and induce anti-tumor responses [10]. However, establishing these differences in clinical
28 samples has been difficult due to heterogeneity in dose regimens and RT delivery methods.

1 Presently, it is also unclear whether the clinical response seen with HDRBT results from direct action toward
2 PCa cells, cancer associated fibroblasts, the immune system or any combinations of these. For this reason, we
3 have specifically explored these three potential response mechanisms to HDRBT in a cohort of patients with
4 localized PCa. We previously revealed PCa stromal cell gene expression and proteomic responses to HDRBT
5 as well as dosimetric features [11-13]. In this current study, we used the same patient cohort to evaluate
6 localized PCa immune response to HDRBT. To do this, we assessed a cohort of 24 paired pre- and post-
7 HDRBT PCa samples for changes in tumor inflammation gene signatures and multiplex IHC. Contrasting this
8 information with alterations in immune cell densities, cell associations and spatial relationships revealed the
9 capacity for HDRBT to fundamentally alter the tumor immune microenvironment.

10

11

12

13

1 **Materials and Methods**

2 Complete methods and materials, including supporting quality control information are provided in
3 Supplementary Information.

4

5 *Patient cohort and sample collection*

6 **Table 1** shows the clinical characteristics of 24 patients with localized PCa analyzed in this study. Patients
7 had two HDRBT treatments performed 14 days apart with a 10Gy fraction prescribed to the target volume
8 (whole prostate) on each occasion. Full details of radiation therapy delivery, including sample processing,
9 histopathological assessment, and ethics approval are provided in Supplementary Information. All participants
10 provided consent covering tissue research as part of a prospective tissue collection study for prostate
11 radiobiology research, approved by the Human Research Ethics Committee at the Peter MacCallum Cancer
12 Centre (PMCC; HREC approvals 10/68, 13/167, 18/204).

13

14 *Multiplex IHC*

15 3 µm FFPE tissue sections from each biopsy were mounted on an adhesive slide, deparaffinized and rehydrated
16 by serial passage through changes of xylene and graded ethanol for multiplex immunohistochemistry staining
17 with the T cell Panel and Pan Immune Panel as described previously [14]. Full details for imaging, cell
18 segmentation, data processing and quality control are provided in Supplementary Information. An example of
19 the experimental pipeline is shown in **Supplementary Figure S1** and quality control data are shown in
20 **Supplementary Figures S2, S3 and S4**. Further information is provided in the Supplementary material.

21

22 *Nanostring and 3' RNAseq immune gene expression profiling*

23 RNA was isolated and purified from 10 µm tissue sections using the RNeasy FFPE kit (Qiagen) according to
24 the manufacturer's instructions. Full details for nCounter PanCancer Immune Profiling Panel and 3' RNAseq
25 analyses are provided in the Supplementary Information.

26

27 *Digital Spatial Profiling*

28 3 µm serial sections of post-HDRBT biopsies from patients RB019 and RB023 were processed by Nanostring
29 Technologies using the ImmunoOncology (IO) RNA and protein panels and analyzed using a GeoMx. Sections

1 were stained prior to ROI selection (12 ROIs per section) with CD3, CD68, Pan-Cytokeratin (PanCK) and
2 DAPI to enable rational selection of regions. Raw data was normalized to both External RNA Control
3 Consortium (ERCC) spike-in and signal-to-noise control. These normalized data were used for generation of
4 TIS signature (mean of all normalized values in TIS signature).

5 *Data Analysis, bioinformatics and statistical considerations.*

6 Full details for data analyses, as well as statistical tests and power calculations are provided in the
7 Supplementary Information.

8

1 **Results**

2 Clinical and histopathological features of the twenty-four patients who underwent HDRBT for localized pros-
3 tate cancer are summarized in **Table 1**. Forty eight tissue samples were obtained from these patients, and
4 analyzed as depicted in **Figure 1A**. H&E sections from these paired biopsies were viewed by an experienced
5 uropathologist to mark the location of tumor-bearing tissue within the core (**Figure 1B**). Immune gene expres-
6 sion changes in response to radiation were evaluated using the Nanostring PanCancer Immune Profiling panel,
7 digital spatial profiling (DSP) and the TIS gene signature. Serial sections were used as input for multiplex IHC
8 (mIHC) on two different multiplex panels (pan-immune or T cell-specific) to enumerate 12 distinct cell subsets
9 (refer to **Table 2** for cell phenotypes). Using the multiplex IHC data, we derived immune subset density (cells
10 per mm²) and spatial characteristics (median cell-to-cell distance), and correlated this with immune gene ex-
11 pression data, immune network signaling and the Nanostring tumor inflammation score.

12 13 **Profiling the transcriptional activation response of PCa to HDRBT**

14 We hypothesized that HDRBT alters the local immune signaling network of PCa, and that this would be
15 evident in changes in immune activation and signaling at the transcriptional level. We therefore used an
16 established immune profiling gene expression platform and robust signature of clinically-relevant immune
17 activation to broadly assess how immune-related genes and regulatory pathways were perturbed by radiation.

18 *The Tumor Inflammation Signature (TIS) depicts heterogeneity in prostate cancer response to HDRBT*

19 To gain a better understanding of the functional state of the immune system in the biopsies, we first employed
20 a modified investigational 18-gene expression profile (GEP) known as the Tumor Inflammation Signature
21 (TIS) [15]. This signature identifies the presence of an inflamed immune infiltrate in tissues associated with
22 activation of the IFN γ pathway, antigen presentation and T cell activation – and classifies tissues into three
23 broad categories: high, intermediate, or low [16]. The TIS is also associated with an inflamed but
24 immunosuppressed phenotype in many different cancer types that is also correlated with good responses to
25 checkpoint blockade [16]. We used a modified TIS signature containing 16 of the 18 genes available from the
26 full signature. We used hierarchical k-means clustering of the z-score-normalized expression data of the 16
27 genes in 46 biopsy samples to delineate categories based on the TIS genes. The results of this analysis, shown
28 in **Figure 2A and B**, revealed a smooth distribution of the 46 pre-HDRBT samples over the three clustered

1 categories (19 low, 14 intermediate, and 13 high). These three immune gene expression profile (GEP)
2 categories were driven by discrete clusters of genes as indicated by the dotted boxes in **Figure 2A**. These gene
3 clusters included increased expression of IFN- γ response genes (e.g. *CXCL9*, *PDL1*, *STAT1* and *PSMB10*
4 bottom box), as well as CD8⁺ T cell infiltration, co-stimulation and chronic activation genes (*CD8A*, *TIGIT*,
5 *Lag3*, *CD27*, *CCL5*, *CXCR6* upper box). The TIS-high category samples had increased expression of IFN- γ
6 response and chronic T cell activation genes; in contrast, the TIS-intermediate samples had increased
7 expression of the IFN- γ response genes only. The TIS-low samples had no evidence of an IFN- γ response or
8 T cell activation (**Figure 2A**). Importantly, this heatmap depicts the pre-HDRBT samples and their change in
9 TIS category post-HDRBT, shown as white circles (low TIS), orange circles (intermediate TIS) and red circles
10 (high TIS) (**Figure 2A**). A more extensively annotated heatmap, including clinical characteristics, is also
11 provided in **Supplementary Figure S5**. Prior to HDRBT, only 34.8% of the tissues were classified as either
12 high or intermediate TIS - with 65.2% (15/23) of the biopsies being classified as low TIS. Following HDRBT,
13 we observed a statistically significant (Chi-squared test; $p = 0.008$) increase in the proportion of tissues
14 harboring a high or intermediate class TIS signature (82.6%; 19/23 tissues) (**Figure 2C**). Following radiation,
15 the overall mean TIS expression significantly increased post-HDRBT, with only 4/23 (17.4%) patients
16 exhibiting a low TIS score after HDRBT (**Figure 2D**). We also confirmed that the HDRBT-induced PCa TIS
17 increase was patient-specific and not stochastic (**Supplementary Figure S6**). We then focused our analysis
18 on the pre-HDRBT low TIS samples and found the vast majority (80%; 12/15) were converted to either an
19 intermediate TIS (46.7%) or high TIS (33.3%). The remaining three patients did not respond to the radiation
20 in terms of TIS (RA014, RA025 and RB050), with no clear underlying clinical (e.g. Gleason Grade) or
21 experimental cause (**Supplementary Figure S6**). A bioinformatics analysis suggested that latent immune
22 activation in baseline tissue (e.g. IFN γ and TNF β pathways) was associated with a good TIS response to
23 HDRBT (**Supplementary Figure S7**).

24 Immune checkpoint (IC) molecules were significantly changed (Paired Wilcoxon test; $p < 0.001$, **Figure 2E**) in
25 response to HDRBT, including genes encoding PDL2, TIM-3, B7-H3, PDL1, CTLA4, GITR, BTLA and
26 CD40. HDRBT-unresponsive IC molecules included PD-1, LAG3, 4-1BB and A2AR. TGF β (in the form of
27 its mRNA transcript *TGFBI*) is also strongly and significantly upregulated following radiation
28 (**Supplementary Figure S6B**).

1 *Immunotranscriptomic profiling the response of PCa to HDRBT*

2 To more broadly describe immune gene expression changes induced by HDRBT, we interrogated all 770 genes
3 evaluated by the Nanostring nCounter PanCancer Immune Profiling platform. Using a two-sample t-test, we
4 identified 59 highly significant (false discovery rate = 0) genes that were differentially expressed in response
5 to HDRBT (**Supplementary Figure S8A**). More in-depth analysis of these candidates revealed the strong
6 overexpression of the p53 pathway and DNA damage-related genes (e.g. *CDKN1A/p21* and *BAX*)
7 (**Supplementary Figure S8B**). The monocyte/macrophage markers *CD163* and *CD14* were also highly
8 expressed genes – both were identified in our previous pilot studies [11-13]. Amongst the T cell specific
9 markers, we identified *LILRB2*, *CD86* and *IL2RA* - the latter of which is typically expressed on CD4⁺FOXP3⁺
10 Tregs and activated CD4⁺ T cells. Gene pathway analysis of the 59 candidates using EnrichR confirmed the
11 enrichment of genes associated with CD14⁺ monocytes and the CD33⁺ myeloid lineage (**Supplementary**
12 **Figure S8C**: Human Gene Atlas database), and macrophage, inflammation and complement activation
13 markers (**Supplementary Figure S8D**: Wiki Pathways). We identified the immune response was diverse and
14 included the four main immune pathways assessed by the gene panel (innate, humoral, adaptive and
15 inflammatory; **Supplementary Figure S8E**). Importantly, we verified that changes in gene transcripts
16 encoding the mIHC markers used for Opal analysis reflect the overall density changes observed via multiplex
17 IHC in later results – which was an important cross platform validation of our findings (**Supplementary**
18 **Figure S9**).

19 Taken together, our gene expression data suggests that HDRBT induced inflammation (as measured by TIS)
20 exists in the majority of samples. However, this gene expression data is derived from bulk RNA, with several
21 samples not harboring tumor zones. This supports the concept that the overall response is at least partially
22 driven by the surrounding stromal tissue compartment rather than explicitly by tumor cells alone. Assessing
23 these changes at a more detailed cellular level is crucial for unravelling the role of different immune cell types
24 and tissue areas in driving differential responses to HDRBT. Therefore, we next employed digital spatial gene
25 and protein expression profiling to understand this response in more detail in representative patients.

26

27 **Digital spatial profiling identifies tissue-specific TIS changes driven by complex immune infiltrate.**

28 We then explored the cellular source of TIS expression, its dependency on the presence of tumor, and the cause
29 of the different two TIS expression patterns (i.e. intermediate and high). To do this, we selected two patients

1 that exhibited either an intermediate (RB023) or high (RB019) TIS response to HDRBT (**Figure 3A**) and used
2 Nanostring digital spatial profiling to determine TIS expression. IHC staining was performed with DAPI, CD3,
3 CD68 and Pan-cytokeratin targets to define cell distribution (**Supplementary Figure S10A**) prior to regions
4 of interest (ROIs) selection. Twelve ROIs were selected per patient sample (24 total) to include either tumor
5 or non-tumor zones (**Supplementary Figure S10B**), and to contain a variety of T cell and M ϕ infiltration
6 (**Supplementary Figure S11**) (marked by CD3⁺ or CD68⁺, respectively). Using matched ROIs in adjacent
7 serial sections, we performed either RNA or protein IO (immuno-oncology) analyses using 78-plex RNA or
8 55-plex protein DSP IO panels, respectively. We first evaluated the relative expression of TIS in each patient
9 ROI (**Figure 3B**). K-means hierarchical clustering identified two groups of ROIs (high or low) on the basis of
10 total TIS expression in both patients. This analysis did not completely segregate non-tumor and tumor-bearing
11 ROIs. We also confirmed that minor differences in surface area of the ROIs did not affect TIS expression
12 (**Supplementary Figure S10C**). To further explore the nature of TIS expression, we profiled the 24 ROIs for
13 mean TIS expression and identified the highest and lowest-expressing tissue sites. This analysis, shown in
14 **Figure 3C and D**, revealed that the top TIS-expressing sites in both patients were in non-tumor zones. This
15 analysis also revealed the highest TIS ROIs (**Figure 3C-D, upper panels**) also contained a large gross immune
16 infiltrate characterized by both CD3⁺ T cells and CD68⁺ M ϕ . The lowest TIS ROIs were more variable between
17 the patients. RB019, an overall high-TIS class tissue, exhibited low TIS expression in tumor sites irrespective
18 of immune infiltrate levels (**Figure 3C; lower panel**). Conversely, low TIS ROIs in RB023 (intermediate TIS
19 responder) were marked by a combination of tumor and non-tumor sites, yet largely absent T cell and M ϕ
20 infiltrate (**Figure 3D; lower panel**). To more robustly define this difference, we directly compared the mean
21 ROI TIS levels between non-tumor and tumor sites for both patients (**Figure 3E**). This analysis revealed that
22 patient RB019 exhibited significantly higher TIS expression in non-tumor zones, whilst RB023 indicates a
23 similar but not statistically significant difference. This analysis also confirmed that post-HDRBT tissue in
24 RB019 has a higher overall TIS activation as a whole when compared to RB023 ($p < 0.0001$) - consistent with
25 the analysis in **Figure 2**.

26 To understand which immune proteins are linked with TIS expression, we correlated the DSP protein data (55
27 proteins) with RNA TIS scores for matched ROIs in the full set of 24 ROIs. The protein results were also
28 subdivided into cell profiling (**Figure 3F**), immune checkpoints (**Figure 3G**), immune activation (**Figure 3H**),
29 and pan-tumor markers (**Supplementary Figure S10D**) categories to identify the primary molecules in each

1 group. Using all 24 ROIs, we detected positive associations between markers of CD8⁺ T cells (CD45, CD3,
2 CD8 and GZMB), MHC Class II (HLA-DR), Tregs (FOXP3), and B cells (CD20). Interestingly, we also iden-
3 tified a strong inverse correlation between CD56 protein levels (primarily a marker of NK, $\gamma\delta$ T cells and
4 activated CD8⁺ T cells) and TIS. We next investigated if IC protein levels may be related to TIS. VISTA,
5 IDO1, 4-1BB and Tim-3 were all positively associated with TIS (**Figure 3G**). Conversely, CTLA4 and PD-1
6 were higher in areas of low TIS, which may indicate activated Tregs and corresponding immunosuppression.
7 Importantly, many of these molecules were also shown to be upregulated overall in the tissue following
8 HDRBT in **Figure 2E**. Finally, we interrogated associations with proteins involved in immune activation and
9 co-stimulation (**Figure 3H**). Similar to previous results, we identified that CD27, CD80, CD25, CD127, CD40
10 and ICOS were all positively correlated with TIS.

11 In summary, the DSP data in two cases suggests that the HDRBT-induced TIS we observed in **Figure 2A** is
12 broadly driven by a mix of infiltrative immune cells that includes CD8⁺ T cells, Tregs, macrophages and DCs.
13 Immune-absent surrounding tissue possessed a relatively low TIS. Moreover, TIS responses were more pro-
14 nounced in the case with a high TIS category (patient RB019) in non-tumor areas. Such areas also do not seem
15 to correlate with any other cell types aside from CD8⁺ T cells. Alternatively, intermediate TIS zones (patient
16 RB023) appeared to be unaffected by the presence of tumor and possess a highly diverse immune context (T
17 cells + M ϕ + DC etc.). Our results also suggest that TIS levels were linked with IC expression including IDO1,
18 VISTA and Tim3, and potentially inhibited by PD-1 and CTLA4.

19 **HDRBT-induced immune cell density alterations in PCa are dominated by regulatory T cells, DCs and** 20 **macrophages.**

21 The next stage of the study used multiplexed immunohistochemistry (mIHC) and computational analysis of major
22 immune cell types and how they are altered following HDRBT in PCa. In order to further understand the
23 impact of radiation on the immune contexture of PCa, we first evaluated cell density (cells per mm²) for all
24 subsets in all tissue regardless of the presence of tumor. The results, shown in **Figure 4A**, revealed that the
25 overall density of immune cell subsets was not affected by radiation. The dominant cell populations present in
26 the tissue were T cells, primarily comprised of CD4⁺ T cells and DNTs. Minor cell populations included PDL1⁺
27 macrophages and DCs, Tregs and CD8⁺ T cells. Statistical analysis revealed that Tregs and PDL1⁺ macrophage
28 densities were significantly increased post-HDRBT.

1 As radiation is hypothesized to drive differential immune responses in prostate tumor tissue, we next assessed
2 the impact of the presence of tumor on the immune context. The results revealed that the changes established
3 by looking at whole tissue (i.e. Tregs and PDL1⁻ macrophages) were largely maintained in both tumor and
4 non-tumor zones (**Figure 4B**). However, we did observe that PDL1⁻ DCs exhibited an increase in density post-
5 HDRBT in both non-tumor ($p < 0.05$) and tumor zones ($p = 0.17$). PDL1⁻ macrophages exhibited the most
6 interesting pattern of infiltration, with a small but statistically robust density increase that was higher in tumor
7 zones compared to non-tumor - potentially driven by the preferential phagocytotic response to tumor cell
8 damage and apoptosis following HDRBT. PDL1⁺ APCs (M ϕ and DC) were a very minor population and
9 exhibited no change in response to HDRBT. As expected, the density of HMWCK⁺ cells was lower in tumor
10 zones and highly sensitive to HDRBT. PDL1⁺ HMWCK⁻ cells, a mix of tumor and normal stromal cells were
11 uniquely decreased in tumor zones. The decreased density of stromal/tumor cells that express PDL1, along
12 with increased PDL1-expressing APCs in the tumor sites, is potentially indicative of zone-specific cell death
13 from ionizing radiation (e.g. DNA damage-induced apoptosis), inflammation, and subsequent recruitment of
14 macrophages to the irradiated site. The results of this analysis revealed the immune cell density in prostate
15 tissue is heterogeneous and surprisingly resilient to HDRBT; evident in only modest changes in cell densities.

16 **The Tumor inflammation signature is associated with radioresponsive immune cell relationships**

17 Localized immune network signaling occurs following key interactions between immune cells (e.g. antigen
18 presentation between DCs and cytotoxic T cells). We hypothesized that HDRBT also alters relative density
19 associations as well as spatial features (i.e. distance) between key immune cell subsets. Similar to the overall
20 density of certain immune subset, this is also hypothesized to influence TIS activation levels.

21 *Cell density associations in non-tumor and tumor zones are perturbed by HDRBT*

22 We first performed an analysis of the correlations between different immune subsets in all samples and
23 included both tumor and non-tumor tissue zones. This revealed that numerous immune cell densities were
24 significantly correlated in our PCa cohort (**Supplementary Figures S12A and S12B**) regardless of tumor
25 content. These subset pairs include T cells/B cells, CD4⁺ T cells/Tregs, and PDL1⁻ APCs (DC and M ϕ) with
26 CD4⁺ T cell subsets (CD4⁺ T cell and Treg). When cell densities were subdivided by tissue zone and irradiation
27 status, only a proportion of these associations are retained in common (e.g. CD4⁺ T cell and Treg) and most

1 were restricted to each tissue type without a clear pattern (**Supplementary Figure S12C**). We therefore
2 performed a differential Pearson correlation analysis to better resolve these differences. The results of this
3 analysis (**Figure 5A**) revealed only two association gains were conserved between the two tissue zones,
4 between PDL1⁺ DC and PDL1⁺ M ϕ , and Tregs and B cells. The strongest post-radiation changes in tumor
5 zones only included a gained association between T cells and PDL1⁺ HMWCK⁺ cells. Interestingly, this
6 occurred in parallel with lost associations between T cells and both PDL1⁺ macrophages and B cells. Following
7 HDRBT, both Tregs and CD4⁺ T cells were more associated with PDL1⁺ HMWCK⁻ in the tumor zone only.
8 The interaction of PDL1⁻ DCs with their PDL1⁺ counterparts, as well as with PDL1⁺ macrophages and B
9 cells, were also preferentially lost in tumor zones. Taken together, this analysis renders a picture of radiation-
10 induced changes in associations between T cells and APC subsets that appears to be influenced by the presence
11 of tumor.

12 To understand if the densities of immune subsets correlate with changes in tumor inflammation (TIS), we next
13 correlated total, tumor and non-tumor immune subset densities with the TIS signature using Pearson r analysis.
14 The results (**Figure 5B and Supplementary Figure S13**) confirmed that CD3⁺ T cells, Tregs, CD4⁺ T cells
15 and M ϕ all correlate significantly with TIS. Perhaps most interesting was that these correlations were most
16 significant in non-tumor tissue, with the exception of CD3⁺ T cells. DC's were also observed to correlate with
17 TIS in non-tumor zones. Overall, this suggests that immune cells in non-tumor areas are responsible for
18 changes in TIS. To support this, we next compared the relative density of Treg, DC and M ϕ between tumor
19 and non-tumor zones (**Figure 5C**). This analysis confirmed that all were strongly correlated, suggesting other
20 factors are likely involved. These data suggest many immune subsets are strongly correlated, and also
21 responsive to radiation in terms of TIS. We therefore compared the most potent combinations (**Figure 5D**) and
22 revealed that some are highly correlated (CD4⁺ T cells/Tregs and B cell/T cell) and some non-correlated
23 (Treg/M ϕ). Overall, this density analysis reinforces the notion that specific combinations of immune cell
24 relationships are more important to the HDRBT TIS response than others.

25 *Tumor-specific immune cell distance relationships are tightly linked with the TIS response to HDRBT*

26 Another major determinant of immune signaling in tissue is the spatial relationships between key immune cell
27 subsets. To address this, we used the spatial information within the multiplex IHC dataset to characterize the
28 median distance between all immune cell subsets (**Supplementary Figure S14**). This resulted in a total of 72

1 unique interactions over the two multiplex IHC panels in each of the four tissue types according to tumor and
2 radiation status. We first used ANOVA analysis to shortlist those spatial relationships with statistical
3 difference, and identified seven with some degree of variation between the four groups (**Supplementary Table**
4 **3**). The most significant changes were observed between CD8⁺ T cell/CD8⁺ T cell ($p < 0.00097$), T cells/DCs
5 ($p < 0.0048$), and Mφ/DC ($p < 0.0072$). Other significant differences were observed between DNT/Treg, B
6 cells/DC PDL1⁺, CD4⁺ T cells/CD8⁺ T cells, and HMWCK-PDL1⁺/ CD8⁺ T cells. We next performed a
7 statistical pairwise Wilcoxon test analysis to resolve specifically where these changes occurred (**Figure 6A**).
8 We revealed that the main spatial response to radiation was a decrease in distance between T cells/DC and
9 Mφ/DC decreases in both tumor and non-tumor zones. Conversely, the only spatial proximity which was lost
10 was between CD8⁺ T cells as a whole. We also observed that DNT and Tregs were closer together in tumor
11 areas.
12 Similar to the previous density analysis, we next compared the median distance between all 72 subsets and the
13 normalized TIS expression level. The results, shown in **Figure 6B**, showed that 29/72 interactions were influ-
14 enced TIS. There was a significant difference according to tumor status, with 67% and 33% being associated
15 with TIS in non-tumor and tumor zones, respectively. This corroborates our previous density analysis which
16 suggested that the non-tumor areas are most important for TIS activation. Also, the bulk of these correlations
17 (70%) were negative, largely in post-HDRBT tissue (100% of non-tumor, 83% of tumor zones). Some of the
18 most significant examples of these changes are provided in **Figure 6C**. Overall, this analysis suggests that
19 close cell-cell interactions are key for increased TIS activation following HDRBT. However, we did observe
20 one post-HDRBT increase at a distance that was specific to tumor zones, between T cells and B cells.
21

1 **Discussion**

2 Clinical outcomes for patients with localized PCa are linked to features such as the serum prostate-specific
3 antigen level, tumor stage and grade, along with treatment factors. Patients with more aggressive clinical
4 features however have higher rates of recurrence with all treatment options [1, 4], including with HDRBT, and
5 these recurrences may be either local or metastatic [17] and significantly impact survival [18].
6 Key to improving outcomes from HDRBT is the detailed understanding of cellular and molecular responses
7 to the radiation, with a view to design of rational combination approaches. Here we have specifically explored
8 HDRBT-induced immune responses in PCa at the level of gene expression signatures and infiltrative immune
9 cells, and also asked whether these changes were driven by tumor cells or surrounding tissue. This is the first
10 study to analyze immune responses to HDRBT in localized human PCa. The immune context of localized PCa
11 has thus far only been explored in cells isolated from radical prostatectomy samples [6, 19-23]. Prior studies
12 showed PCa infiltrating lymphocytes (PILs) included CD8⁺ effector memory T cells [21] which were
13 oligoclonal and PD-1⁺ [22], accompanied by increased regulatory CD4⁺ and CD8⁺ T cells with suppressor
14 function [19, 20]. In addition, IHC showed PCa lesions were surrounded by lymphocyte clusters enriched for
15 FOXP3⁺, PD-1⁺, and PDL1⁺ cells [6]. Thus, the emerging picture for PCa is one of immune exclusion and
16 immune suppression.
17 Our results revealed that PCa tissues have immune activation states in three distinct TIS levels with two-thirds
18 of pre-HDRBT tissues having a low TIS - indicating an inactive immune microenvironment. This distribution
19 was reversed following radiation, with over 80% of tissues possessing a high or intermediate TIS after
20 HDRBT. Using a combination of multiplex IHC and digital spatial gene and protein profiling (DSP), we
21 showed this TIS change is intimately linked with several immune cell densities, specifically those of active T
22 cell subtypes and APCs - supporting the notion that the two processes are linked. The DSP analysis also
23 revealed that the strongest TIS responses are driven primarily by non-tumor zones, and was associated
24 primarily with CD8⁺ T cells. Conversely, intermediate TIS is agnostic to tumor and is linked with a much more
25 diverse group of T cell and APC cell subtypes. The presence of numerous therapeutically significant IC
26 molecules in conjunction with TIS in two selected cases, including VISTA, IDO1, 4-1BB and Tim3, raises
27 possibilities for combination treatment with HDRBT. Both VISTA and IDO1 were associated with tumor
28 resistance in ICB-treated prostate cancer [24, 25]. Whether these IC molecule changes are drivers or responders
29 to HDRBT-induced responses remain to be seen but warrants further investigation in additional patients and

1 radiation states. Overall, these results reveal that immune signaling gene expression is profoundly influenced
2 by HDRBT and is not confined to tumor areas. A caveat of our study is that the biopsy procedure, in
3 conjunction with HDRBT, could contribute to inflammatory and wound healing responses in the tissue.

4
5 To further understand the potential cellular drivers of this response, we used multiplexed IHC to characterize
6 the immune cell environment before and after HDRBT. This revealed that Tregs, M ϕ and DCs were the
7 predominant cellular density change in response to HDRBT. TGF β , which was highly expressed post-radiation
8 is also an immunosuppressive cytokine in prostate cancer and linked with the presence of Tregs and M ϕ [26].
9 This occurred in the context of the majority of other immune cell types which did not alter in density, yet likely
10 repopulated the TME to a similar level following the ablative dose of radiation. Interestingly, DNTs
11 represented a relatively large fraction of T cells in both pre- and post-HDRBT conditions (~35% total T cells).
12 Whilst interesting, our analysis could not further resolve this population due to the absence of appropriate
13 markers for putative sub-types of DNTs (e.g. $\gamma\delta$ T cells, MAIT cells, NKT cells). Despite relatively few cells
14 significantly changing in overall density, we observed numerous cell association changes following radiation,
15 predominately between PDL1⁺ APCs and T cell subsets. For Tregs and DCs, this effect was largely observed
16 to occur in all areas of PCa tissue. However, the density of PDL1⁻ macrophages is positively influenced by the
17 presence of tumor– potentially indicating the presence of M2 polarized tumor-associated macrophages
18 (TAMs). This observation was supported by the Nanostring gene expression profiling which revealed markers
19 of M2 TAMs [27], notably CD14, CD163, HLA-DRA and CD68, were enriched post-HDRBT. This
20 observation was also noted in our existing proteomic analyses of post-HDRBT PCa tissue [13]. The presence
21 of large numbers of T cell subsets after this substantial dose of radiation may indicate trafficking of new T
22 cells.

23 Immune checkpoint molecule expression in cancer tissue is of paramount importance to the efficacy of immune
24 checkpoint blockade drugs [28]. We identified a large number of changes in many IC molecules, and all
25 increased following HDRBT. Despite not being certain of the cellular source of these molecules, increased
26 PDL1 and PDL2 expression is consistent with the observed increases in M2 macrophages and DCs, however,
27 our multiplex IHC analysis of PDL1 expression on these cells does not support this conclusion. We instead
28 observed *decreases* in PDL1⁺-expressing HMWCK⁺ (basal glands) and HMWCK⁻ (tumor, epithelial,
29 fibroblast) cells after HDRBT. This suggests that the source of increase in PDL1 expression is likely to be

1 from cells that were not assessed by mIHC, either by differences in antibody clone specificity or simply that
2 its expression is tightly controlled at the translational level. CTLA4 and TIM3 are both highly expressed on
3 Tregs [29, 30], and high expression of B7-H3 and CD40 are both observed on licensed APCs. Further work
4 will be required to understand the source of these IC molecule changes and to understand how these changes
5 are relevant to the immune response post-HDRBT.

6 A striking observation made through this study related to the changes in the magnitude and diversity of spatial
7 relationships between different cells in both tumor and non-tumor regions in response to HDRBT. Whilst many
8 associations were acutely affected by radiation (e.g. increased proximity of T cell and DCs), further studies
9 exploring T cell function are needed to reveal what this means to the immune response in PCa. These spatial
10 relationship changes could dramatically affect intrinsic immune signaling pathways, we observed that many
11 tissue-specific spatial interactions were strongly linked with TIS signatures (e.g. loss of T cell – B cell
12 proximity in tumor zones). Our DSP data suggests that localized factors either control or are responsive to the
13 TIS response. Importantly, patients appear to exhibit very different responses to radiation. Further work will
14 be required to unravel the clinical importance of these relationship, if they are of predictive value and relevance
15 to therapies.

16 Radiation therapy has the potential to change the solid tumor microenvironment to make this amenable to
17 trafficking and the persistence of T cells. We demonstrated that HDRBT-induced changes in the immune cell
18 density of PCa are restricted to macrophages, DCs, and Tregs. This suggests the observed changes in TIS
19 levels post-HDRBT are the consequence of altered immune cell network signaling, and was correlated with
20 changes in immune subset spatial relationships. This suggests that a significant number of PCa patients have
21 a pre-existing immune response, which is held in check by peripheral tolerance mechanisms. Likely candidates
22 in PCa include high levels of TGF- β and increased Tregs and immune-suppressive macrophages.

23 In terms of the clinical relevance of our findings, existing GEP studies have revealed that Th1-mediated
24 adaptive immunity and inflammatory GEPs are positively associated with good outcome in patients with
25 localized PCa [31]. Additional work has also focused on generating gene expression profiles associated with
26 clinical outcomes, rather than predicting immune responses, which has ramifications for immune-targeted
27 therapies [32].

28

29

1 **Conclusions**

2 Taken together, our findings suggest that strategic therapeutic targeting of immunosuppressive mechanisms
3 (e.g. TGF- β), plus immune checkpoint inhibitors with HDRBT, could help drive a systemic response to PCa.
4 We envisage that this could be used to improve cancer control in those with high-risk disease where outcomes
5 are currently poor, or to enable treatment de-intensification to improve the side-effect profile in those with less
6 aggressive disease treated with RT. Larger numbers of patients with assessment of long-term clinical outcomes
7 will be required to fully understand the full potential of immunotherapeutic approaches in PCa radiotherapy.

8

9 **List of Abbreviations**

10

11	PCa	Prostate cancer
12	HDRBT	High dose-rate brachytherapy
13	TIS	Tumor inflammation signature
14	EBRT	External beam radiation therapy
15	RT	Radiation therapy
16	IHC	Immunohistochemistry
17	mIHC	Multiplexed immunohistochemistry
18	IC	Immune checkpoint
19	ADT	Androgen deprivation therapy
20	PMCC	Peter MacCallum Cancer Centre
21	MRI	Magnetic resonance imaging
22	PET	Positron emission tomography
23	ISUP	International Society of Urological Pathology
24	FFPE	Formalin-fixed paraffin-embedded
25	GG	Gleason grade
26	HIER	Heat-induced epitope retrieval
27	DSP	Digital spatial profiling
28	ROI	Region of interest
29	RB	RadBank
30	GEP	Gene expression profile
31	IO	Immuno Oncology
32	APC	Antigen presenting cell

33

34

1 **Tables**

2 **Table 1: Clinical characteristics of cohort.**

Gleason Grade Group	T-stage	Number of patients	Age (mean ± SD)	PSA (ng/ml)	Neoadjuvant ADT	Relapse
2	1c	4	59.3 ± 7.9	6.1 ± 1.6		
	2a	2	70.5 ± 3.5	7.7 ± 4.6		
	2b	2	70.0 ± 1.4	8.8 ± 1.9		
	<i>Total</i>	8	64.8 ± 8.0	7.1 ± 2.5		
3	1c	5	63.0 ± 4.5	21.6 ± 32.8	Yes	Yes
	2b	3	65.3 ± 4.2	12.1 ± 6.8		
	2c	1	70.0	11.3	Yes	
	3a	1	67.0	11.2		Yes
	3b	1	57.0	80.0	Yes	
	<i>Total</i>	11	64.1 ± 4.7	22.4 ± 28.8	3	
4	1c	1	76.0	27.7	Yes	
	2a	1	70.0	6.1		
	<i>Total</i>	2	73.0 ± 4.2	16.9 ± 15.3	1	
5	2a	1	66.0	6.4		
	2b	1	73.0	7.2	Yes	
	3b	1	67.0	10.3	Yes	Yes
	<i>Total</i>	3	68.7 ± 3.8	8.0 ± 2.1	2	
		24	65.6 ± 6.2	15.1 ± 20.7	6	3

3 **Table 2: Immune subsets assessed by multiplex IHC**

Marker expression	Panel	Cell subset	Abbreviation
CD3⁺CD4⁺CD8⁻	T cell	T-helper	T-helper
CD3⁺CD8⁺CD4⁻	T cell	CD8 ⁺ T cells	CD8 ⁺ T cells
CD3⁺CD4⁺FOXP3⁺	T cell	Regulatory T cell	Treg
CD3⁺CD4⁻CD8⁻	T cell	Double negative T cell	DNT
CD3⁺	Pan Immune	Pan T cell	T cell
CD20⁺	Pan Immune	B cell	B cell
CD68⁺	Pan Immune	Macrophage	φ
CD68⁺CD11c⁺	Pan Immune	Dendritic cell	DC
CD68⁺PDL1⁺	Pan Immune	PDL1 ⁺ Macrophage	φ ^{PDL1+}
CD68⁺CD11c⁺PDL1⁺	Pan Immune	PDL1 ⁺ Dendritic cell	DC ^{PDL1+}
HMWCK⁺PDL1⁺	Pan Immune	PDL1 ⁺ Basal cells	HMWCK ⁺ PDL1 ⁺
HMWCK⁻PDL1⁺	Pan Immune	PDL1 ⁺ Non-basal cells	HMWCK ⁻ PDL1 ⁺

4

1
2

Table 3: Top 20 significantly perturbed median spatial relationships in PCa tissue in response to HDRBT.

<i>Target</i>	<i>Neighbour</i>	<i>ANOVA p-value</i>
<i>CD8+ T cells</i>	CD8+ T cells	0.00097
<i>T cells</i>	DC	0.0048
<i>MΦ</i>	DC	0.0072
<i>DNT cells</i>	Tregs	0.018
<i>B cells</i>	DC PDL1+	0.04
<i>CD4+ T cells</i>	CD8+ T cells	0.04
<i>HMWCK-PDL1+</i>	CD8+ T cells	0.046
<i>T cells</i>	MΦ	0.056
<i>DNT cells</i>	CD8+ T cells	0.06
<i>T cells</i>	DC PDL1+	0.081
<i>HMWCK-PDL1+</i>	Tregs	0.095
<i>CD8+ T cells</i>	HMWCK-PDL1+	0.1
<i>MΦ</i>	DC PDL1+	0.11
<i>HMWCK+PDL1-</i>	CD8+ T cells	0.11
<i>CD4+ T cells</i>	CD4+ T cells	0.14
<i>Tregs</i>	CD8+ T cells	0.16
<i>HMWCK-PDL1+</i>	CD4+ T cells	0.16
<i>B cells</i>	DC	0.17
<i>CD4+ T cells</i>	HMWCK-PDL1+	0.18
<i>DNT cells</i>	HMWCK-PDL1+	0.22

3
4

1 **Figure Legends**

2 **Figure 1: Overview of experimental plan.** (A) Twenty four patients with localised prostate adenocarcinoma
3 were treated with a single 10 Gy dose of high-dose-rate brachytherapy (HDRBT) with image guided biopsies
4 taken immediately prior to and two weeks post-HDRBT. Following formalin fixation and sectioning, samples
5 were processed for (i) histopathological examination and tumor zone categorisation, (ii) Nanostring nCounter
6 Pan-cancer immune gene panel RNA profiling, (iii) digital spatial profiling, (iv) multiplex IHC, and (v) com-
7 putation spatial analysis. (B) Schematic showing tissue zones categorised by histopathology and incorporated
8 into subsequent immune density analyses. T: tumor, NT: non-tumor, HDRBT: high dose-rate brachytherapy,
9 mIHC: multiplex immunohistochemistry, HMWCK: high molecular weight cytokeratin, DC: dendritic cells,
10 M ϕ : macrophage, Treg: regulatory T cells.

11
12 **Figure 2: High dose rate brachytherapy induced a 16-gene tumor inflammatory signature (TIS) in lo-**
13 **calized PCa.** Shown is (A) Heatmap of normalized expression levels of 16 genes in tumor inflammatory sig-
14 nature (TIS) and categorisation by k-means clustering into three groups: (i) Cluster 1, high TIS, (ii) Cluster 2,
15 intermediate TIS, and (iii) Cluster 3, Low TIS. White and black boxes indicate either pre-HDRBT or post-
16 HDRBT tissue, respectively. Colored circles indicate pre-HDRBT samples and their TIS category change post-
17 HDRBT. (B) Averaged and ranked z-scores for the 16 genes in TIS indicated three categories. (C) Proportion
18 of pre- or post-HDRBT tissues in each of the three TIS categories identified in (A), the P-value was calculated
19 from chi-squared test. (D) Violin plot of mean TIS expression levels in patient-matched pre- or post-HDRBT-
20 treated PCa tissue. Wilcoxon matched pair test. * $p < 0.05$, ** $p < 0.01$, ***, $p < 0.001$, **** $p < 0.0001$. (E) Box-
21 and-whisker plots of expression levels of immune checkpoint molecules in pre- and post-HDRBT tissues from
22 all patients in cohort. *TLK2* and *TRIM39* are provided as invariant controls. Significance was assessed using a
23 Wilcoxon matched pair test. * $p < 0.05$, ** $p < 0.01$, ***, $p < 0.001$, **** $p < 0.0001$. † represents RadBank-V1.

24
25
26 **Figure 3: Digital spatial gene and protein expression profiling reveals cellular and immune checkpoint**
27 **drivers of high and intermediate TIS.** Heatmaps of normalized Nanostring TIS gene z-scores in two patients
28 using (A) bulk tissue from pre- and post-HDRBT tissues, or (B) post-HDRBT ROIs (n=24) assessed using

1 digital spatial profiling human IO RNA panel (DSP RNA). Tissue sites were determined using tumor histo-
2 pathology (tumor and non-tumor) and immune cell IHC staining for T cells (CD3) and M ϕ (CD68) (12 ROIs
3 per patient). High magnification examples of highest and lowest TIS-expressing ROIs in post-HDRBT tissue
4 from patient (C) RB019 and (D) RB023. (E) Mean Nanostring DSP-derived TIS scores by tumor category in
5 two patient samples (tumor zones: n=7/12(RB019) and n=5/12(RB023)). Pearson correlation of DSP IO pro-
6 teins in (F) cell profiling, (G) immune checkpoint, or (H) activation protein classes with DSP RNA TIS score.
7

8 **Figure 4: High dose rate brachytherapy significantly increased the density of CD4⁺FOXP3⁺ T cells and**
9 **antigen presenting cells.** Multiplex IHC was performed on PCa biopsies pre- and post-HDRBT (n=24 pa-
10 tients). Shown are (A) Cumulative barplots of mean immune cell density either pre- or post-HDRBT. P-values
11 calculated from two-tailed student's t-test with * indicating p< 0.05. (B) Immune subset density calculated
12 from total number of identified immune phenotypes (see Table 2) per square millimetre pre- or post-HDRBT
13 in each of the two designated tissue zones: (i) non-tumor or (ii) tumor-containing. Statistical significance was
14 calculated using a non-parametric Wilcoxon signed-rank test. P-values are indicated where appropriate.
15 *p<0.05, ** p<0.01, *** p<0.001.

16
17 **Figure 5: Immune cell density relationships correlate with TIS signature.**

18 (A) Computed differences in Pearson correlation (Δr) for either (i) non-tumor and (ii) tumor following
19 HDRBT. Color indicates direction of change, i.e. red = gained association, blue = lost association. Only sig-
20 nificant associations are shown (B) Bubblechart of correlation (Pearson r) between immune cell densities in
21 different tissue zones (total, tumor or non-tumor) and TIS signature. Significant correlations indicated. (C)
22 Scatterplots of highly significant immune cell subset correlations between tumor and non-tumor tissue zones,
23 and (D) highly significant cross-subset correlations in total tissue, with relative TIS level and HDRBT radia-
24 tion-status indicated. (T: tumor zone, NT: non-tumor zone, Tot: all tissue zones). Pearson correlation r values
25 and corresponding p values indicated.

26
27 **Figure 6: Immune cell spatial interactions change following HDRBT and uniquely associate with TIS**
28 **signature.**

1 (A) Box-and-whisker plots of median cell-cell distance in seven significantly altered immune cell subset pairs
2 in four major tissue zones: (i) Pre-HDRBT: Non-tumor zone, (ii) Post-HDRBT: Non-tumor zone, (iii) Pre-
3 HDRBT: Tumor zone, and (iv) Post-HDRBT: Tumor zone. Significance between group is calculated using
4 uncorrected Wilcoxon test. n=17 patients. (B) Bubblechart plot of significant target- and neighbour-cell me-
5 dian distance correlations with TIS signature in four tissue groups. Positive correlations indicate a higher me-
6 dian cell-cell distance association with higher TIS. Only significant ($p < 0.05$) correlations are shown. (C) Ex-
7 amples of highly significant median distance to TIS correlations with Pearson r calculations for each of four
8 categories of tissue. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

9

10

1 **Supplementary Figure S1:** Multiplex IHC experimental overview and example of pipeline for quantification
2 of immune subsets in human prostate cancer tissue biopsies. (A) Workflow of experimental multiplex IHC
3 study. (B) H&E stain and corresponding Opal™ tissue classification of non-tumor (blue) and tumor (red). (C)
4 Raw acquired images from either pan-immune (left) or T cell panels (right). Example high magnification (D)
5 non-tumor zone and (E) tumor zone. (F) Deconvoluted and processed images prior to quantification of cell
6 types. (G) Spatial plot of identified immune subtypes indicating assignment of different cell types on the tissue
7 and their spatial relationship.

8 **Supplementary Figure S2:** The effect of tumor and non-tumor amount on PCa immune context. Using the
9 segmentation data from Figure S1B, each prostate biopsy was depicted by (A) Total area of pathologically
10 defined tumor and non-tumor (mm²). (B) Correlation between tumor proportion and total tissue proportion.
11 (C) Correlation between total tissue area and total immune cell density evaluated by multiplex IHC. Corre-
12 sponding r values are shown with p-values evaluated using Pearsons correlation (95% confidence interval).

13 **Supplementary Figure S3:** Pearson's correlation scatterplots of CD3⁺ cell densities in assessed tissues eval-
14 uated using either Pan-immune or T cell panels. Data was divided by either (A) non-tumor or (B) tumor zones.
15 Dots are coloured by either pre- or post-HDRBT state with corresponding Pearson's r values and p-values
16 shown (95% CI).

17 **Supplementary Figure S4:** (A) TIS score and (B) immune cell densities according to ADT-treatment status
18 in pre-HDRBT biopsies. Paired t-tests used for statistical analysis with p-values indicated.

19

20 **Supplementary Figure S5: High dose rate brachytherapy induced a 16-gene tumor inflammatory signa-**
21 **ture (TIS) in localized PCa.** Figure 2A with inclusion of clinical characteristics. Shown is (A) Heatmap of
22 normalized expression levels of 16 genes in tumor inflammatory signature (TIS) and categorisation by k-means
23 clustering into three groups: (i) Cluster 1, high TIS, (ii) Cluster 2, intermediate TIS, and (iii) Cluster 3, Low
24 TIS. Grey and black boxes indicate either pre-HDRBT or post-HDRBT tissue, respectively. Colored circles
25 within grey boxes (pre-HDRBT) indicate post-HDRBT TIS category change. Other clinical parameters are
26 shown above (i.e. Gleason Grade Group, T-stage, relapse status, and ADT pre-treatment).

1 **Supplementary Figure S6:** (A) Patient line-matched mean TIS expression levels in pre- or post-HDRBT-
2 treated PCa tissue. Red lines indicate increase, blue lines indicate decrease. Significance assessed using Wil-
3 coxon matched pair test. * $p < 0.05$, ** $p < 0.01$, ***, $p < 0.001$, **** $p < 0.0001$. (B) *TGFB1* mRNA levels pre-
4 and post-HDRBT in 24 patients.

5
6 **Supplementary Figure S7: A pre-existing immune response is associated with a tumor inflammatory**
7 **signature response to HDRBT.** Nanostring immune GEP data was examined on paired pre- and post-
8 HDRBT biopsies. Good responders were classified as those that initially had a low tumor inflammation sig-
9 nature (TIS) pre-HDRBT (15 patients; 65% total patients), but were subsequently converted to an intermediate
10 or high TIS post-HDRBT ($n = 12/15$; 80% of low TIS). Poor responders were classified as those with no post-
11 HDRBT change ($n = 3/15$; 20% of low TIS). (A) Z-score gene expression heatmap of significant changes cal-
12 culated using a t-test. (B) Bubblechart of gene set enrichment analysis using curated Hallmark datasets and
13 (C) example summary plots from selected immune signalling pathways (bold). (D) mRNA expression levels
14 of $IFN\gamma$, $IFN\alpha$, and $TNF\beta$ in samples from two low TIS categories (R: responder and NR: non-responder), and
15 intermediate and high TIS categories.

16
17 **Supplementary Figure S8: Nanostring immune profiling of post-HDRBT response in prostate tissue**
18 **from 23 patients.** (A) Volcano plot of post-HDRBT changes in 770 changes in Nanostring panel. FDR = false
19 discovery rate. Highly significant candidates (FDR=0) indicated in dotted line box. (B) Magnification of highly
20 ($n = 57$) significant candidates and colour coding according to assigned function according to Nanostring des-
21 ignations or subsequent gene ontology analyses. Gene ontology analysis of candidates ($n = 59$) using (C) Hu-
22 man Gene Atlas or (D) WikiPathways. (E) Volcano plots of discrete immune gene changes sorted by four
23 functional immune classes defined in the nCounter Nanostring Pan Cancer Immune Panel.

24
25 **Supplementary Figure S9:** (B) Box and whisker plots of transcript expression levels of the 8 IHC markers
26 (*CD3E*, *CD4*, *CD8A*, *CD68*, *ITGAX*, *MS4A1*, *FOXP3* and *PDL1*) either pre- or post-HDRBT that were also
27 assessed in multiplex IHC analysis. Differences were assessed using a Wilcoxon matched pair test. * $p < 0.05$,
28 ** $p < 0.01$, ***, $p < 0.001$, **** $p < 0.0001$.

29

1

2 **Supplementary Figure S10: Digital spatial profiling supplementary information 1.** (A) 4-color (CD3,
3 CD68, DAPI and PanCK) stains of RNA and protein slides with selected ROIS indicated. Scale bar equivalent
4 to 2mm. (B) Flowchart of ROI selection in post-HDRBT tissue in two patients (RB019 and RB023). (C) DSP
5 protein correlation of pan-tumor class (c.f. Figure 4F,G,H)

6

7 **Supplementary Figure S11: Digital spatial profiling supplementary information 2.** IHC of 24 ROIs se-
8 lected for RNA and protein DSP IO panels. Panels are organised by TIS category determined previously (c.f.
9 Figure 4B).

10

11 **Supplementary Figure S12:** Correlation dot plots of normalized TIS scores and immune cell population den-
12 sities for all 46 tissues in cohort. Dots are coloured according to Pearson correlation coefficient value.

13 **Supplementary Figure S13:** (A) Pearson correlation between immune cell subsets in all biopsies (n=24) using
14 total tissue information (tumor + non-tumor). Squares indicate important associations investigated in B. (B)
15 Representative scatterplot correlations between immune cell subsets. 95% confidence interval from Pearson
16 correlation. (C) Bubblechart of pearson correlations when sub-categorised by HDRBT status and tissue zone.
17 Only significant ($p>0.05$) correlations are shown with squares indicating shared correlations between tissue
18 zones.

19 **Supplementary Figure S14:** Graphical illustration of median cell distance calculation used for Figure 7.

20

21

22

23


24

25


1 References

- 2 1. Mottet, N., et al., *EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis,*
3 *and Local Treatment with Curative Intent.* Eur Urol, 2017. **71**(4): p. 618-629.
- 4 2. Williams, S.G., et al., *Use of individual fraction size data from 3756 patients to directly determine*
5 *the alpha/beta ratio of prostate cancer.* Int J Radiat Oncol Biol Phys, 2007. **68**(1): p. 24-33.
- 6 3. Mundt, A.J., et al., *Biologic Basis of Radiation Therapy.* Vol. Holland-Frei Cancer Medicine. 6th
7 edition. 2003.
- 8 4. Khor, R., et al., *Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs*
9 *external beam radiation therapy alone for prostate cancer.* Int J Radiat Oncol Biol Phys, 2013.
10 **85**(3): p. 679-85.
- 11 5. Bostwick, D.G., et al., *Intraepithelial and stromal lymphocytes in the normal human prostate.*
12 Prostate, 2003. **55**(3): p. 187-93.
- 13 6. Ebelt, K., et al., *Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+*
14 *lymphocyte clusters.* Eur J Cancer, 2009. **45**(9): p. 1664-72.
- 15 7. Ma, Y., et al., *How to improve the immunogenicity of chemotherapy and radiotherapy.* Cancer
16 Metastasis Rev, 2011. **30**(1): p. 71-82.
- 17 8. Postow, M.A., et al., *Immunologic correlates of the abscopal effect in a patient with melanoma.* N
18 Engl J Med, 2012. **366**(10): p. 925-31.
- 19 9. Rodriguez-Ruiz, M.E., et al., *Immunological Mechanisms Responsible for Radiation-Induced*
20 *Abscopal Effect.* Trends Immunol, 2018. **39**(8): p. 644-655.
- 21 10. Deloch, L., et al., *Modern Radiotherapy Concepts and the Impact of Radiation on Immune*
22 *Activation.* Front Oncol, 2016. **6**: p. 141.
- 23 11. Keam, S.P., et al., *The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer:*
24 *Analysis of a Prospective Tissue Cohort.* Int J Radiat Oncol Biol Phys, 2018. **100**(1): p. 188-198.
- 25 12. Keam, S.P., et al., *Biodosimetric transcriptional and proteomic changes are conserved in irradiated*
26 *human tissue.* Radiat Environ Biophys, 2018. **57**(3): p. 241-249.
- 27 13. Keam, S.P., et al., *Exploring the oncoproteomic response of human prostate cancer to therapeutic*
28 *radiation using data-independent acquisition (DIA) mass spectrometry.* Prostate, 2018. **78**(8): p.
29 563-575.
- 30 14. Halse, H., et al., *Multiplex immunohistochemistry accurately defines the immune context of*
31 *metastatic melanoma.* Sci Rep, 2018. **8**(1): p. 11158.
- 32 15. Ayers, M., et al., *IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade.* J
33 Clin Invest, 2017. **127**(8): p. 2930-2940.
- 34 16. Danaher, P., et al., *Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation*
35 *Signature (TIS): results from The Cancer Genome Atlas (TCGA).* J Immunother Cancer, 2018. **6**(1):
36 p. 63.
- 37 17. Ennis, R.D., et al., *Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated*
38 *With Similar Survival in High-Risk Localized Prostate Cancer.* J Clin Oncol, 2018. **36**(12): p. 1192-
39 1198.
- 40 18. Xie, W., et al., *Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized*
41 *Prostate Cancer.* J Clin Oncol, 2017. **35**(27): p. 3097-3104.
- 42 19. Kiniwa, Y., et al., *CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.*
43 Clin Cancer Res, 2007. **13**(23): p. 6947-58.
- 44 20. Miller, A.M., et al., *CD4+CD25high T cells are enriched in the tumor and peripheral blood of*
45 *prostate cancer patients.* J Immunol, 2006. **177**(10): p. 7398-405.
- 46 21. Rådestad, E., et al. *Characterization of infiltrating lymphocytes in human benign and malignant*
47 *prostate tissue.* Oncotarget, 2017. **8**, 60257-60269 DOI: 10.18632/oncotarget.19528.
- 48 22. Sfanos, K.S., et al., *Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.*
49 Prostate, 2009. **69**(15): p. 1694-703.
- 50 23. Woo, J.R., et al., *Tumor infiltrating B-cells are increased in prostate cancer tissue.* J Transl Med,
51 2014. **12**: p. 30.
- 52 24. Gao, J., et al., *VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy*
53 *in patients with prostate cancer.* Nat Med, 2017. **23**(5): p. 551-555.
- 54 25. Banzola, I., et al., *Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-gamma and TNF-*
55 *alpha as Potential Biomarker of Prostate Cancer Progression.* Front Immunol, 2018. **9**: p. 1051.

- 1 26. Vanpouille-Box, C., et al., *TGFbeta Is a Master Regulator of Radiation Therapy-Induced Antitumor*
2 *Immunity*. *Cancer Res*, 2015. **75**(11): p. 2232-42.
- 3 27. Roszer, T., *Understanding the Mysterious M2 Macrophage through Activation Markers and Effector*
4 *Mechanisms*. *Mediators Inflamm*, 2015. **2015**: p. 816460.
- 5 28. Kythreotou, A., et al., *PD-L1*. *Journal of Clinical Pathology*, 2018. **71**(3): p. 189-194.
- 6 29. Gao, X., et al., *TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated*
7 *with lung cancer progression*. *PLoS One*, 2012. **7**(2): p. e30676.
- 8 30. Takahashi, T., et al., *Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells*
9 *constitutively expressing cytotoxic T lymphocyte-associated antigen 4*. *J Exp Med*, 2000. **192**(2): p.
10 303-10.
- 11 31. Rubicz, R., et al., *Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men*
12 *diagnosed with clinically localized prostate cancer*. *Mol Oncol*, 2017. **11**(2): p. 140-150.
- 13 32. Hsu, D.S., et al., *Immune signatures predict prognosis in localized cancer*. *Cancer Invest*, 2010.
14 **28**(7): p. 765-73.
15




A




B




C












E




D









A



B



C



D

